Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

Published:2011-07-25 Issue:17 Volume:17 Page:5765-5773
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Saad Fred,Hotte Sebastien,North Scott,Eigl Bernie,Chi Kim,Czaykowski Piotr,Wood Lori,Pollak Michael,Berry Scott,Lattouf Jean-Baptiste,Mukherjee Som D.,Gleave Martin,Winquist Eric

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress;Molecular Therapy - Nucleic Acids;2024-09

2. Clusterin: a marker and mediator of chemoresistance in colorectal cancer;Cancer and Metastasis Reviews;2024-02-06

3. The Ins and Outs of Clusterin: Its Role in Cancer, Eye Diseases and Wound Healing;International Journal of Molecular Sciences;2023-08-24

4. Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation;Cancers;2021-11-05

5. Antisense drug discovery and development technology considered in a pharmacological context;Biochemical Pharmacology;2021-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP